NCT02138695 The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort Study
| NCT ID | NCT02138695 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,100 participants |
| Start Date | 2014-05 |
| Primary Completion | 2029-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,100 participants in total. It began in 2014-05 with a primary completion date of 2029-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1\. Purpose of the study 1\) To explore clinical recurrence associated clinical factors including age, sex, clinical, electrophysiological, anatomical, imaging, and serologic characteristics. 2\) To develop simulation model to predict clinical recurrence and the efficacy of catheter ablation 2. Scientific evidence of the study 1. In atrial fibrillation patients, the maintenance of normal sinus rhythm showed significant reduction of mortality. 2. drug therapy with anti-arrhythmic drug showed many complications and side effect, thus non-drug therapy such as catheter ablation is developed. 3. catheter ablation has been performed for 10years world-wide, and showed superior treatment outcome compared with drug therapy. 4. clinical outcome after catheter ablation is affected not only by age, sex and underlying disease, but also by electrophysiologic, imaging, serologic and electroanatomical remodeling of the heart. However, there are few studies concerning these multifactorial variables. 3\. Study population
Eligibility Criteria
Inclusion Criteria: * patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation Exclusion Criteria: * patients who do not agree with study inclusion * permanent AF refractory to electrical cardioversion * AF with valvular disease ≥ grade 2 * patients with left atrial diameter greater than 60mm * patients with age less than 19
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02138695 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02138695 currently recruiting?
Yes, NCT02138695 is actively recruiting participants. Contact the research team at hnpak@yuhs.ac for enrollment information.
Where is the NCT02138695 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT02138695 clinical trial?
NCT02138695 is sponsored by Yonsei University. The trial plans to enroll 3,100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.